152 related articles for article (PubMed ID: 21047593)
1. Lead-time in the European Randomised Study of Screening for Prostate Cancer.
Finne P; Fallah M; Hakama M; Ciatto S; Hugosson J; de Koning H; Moss S; Nelen V; Auvinen A
Eur J Cancer; 2010 Nov; 46(17):3102-8. PubMed ID: 21047593
[TBL] [Abstract][Full Text] [Related]
2. Detection of prostate cancer: the impact of the European Randomized Study of Screening for Prostate Cancer (ERSPC).
Schröder FH
Can J Urol; 2005 Feb; 12 Suppl 1():2-6; discussion 92-3. PubMed ID: 15780157
[TBL] [Abstract][Full Text] [Related]
3. Why are a high overdiagnosis probability and a long lead time for prostate cancer screening so important?
Barry MJ; Mulley AJ
J Natl Cancer Inst; 2009 Mar; 101(6):362-3. PubMed ID: 19276451
[No Abstract] [Full Text] [Related]
4. Detection rates of cancer, high grade PIN and atypical lesions suspicious for cancer in the European Randomized Study of Screening for Prostate Cancer.
Laurila M; van der Kwast T; Bubendorf L; di Lollo S; Pihl CG; Ciatto S; Hugosson J; Määttänen L; Roobol MJ; Kujala PM
Eur J Cancer; 2010 Nov; 46(17):3068-72. PubMed ID: 21047588
[TBL] [Abstract][Full Text] [Related]
5. PSA levels and cancer detection rate by centre in the European Randomized Study of Screening for Prostate Cancer.
Otto SJ; Moss SM; Määttänen L; Roobol M; Zappa M; Nelen V; Kwiatkowski M; Villers A; Hugosson J; Sanchez AB; de Koning HJ
Eur J Cancer; 2010 Nov; 46(17):3053-60. PubMed ID: 21047586
[TBL] [Abstract][Full Text] [Related]
6. Epilogue: different approaches for prostate cancer screening in the EU?
Schröder FH; Denis L; Roobol MJ
Eur J Cancer; 2010 Nov; 46(17):3120-5. PubMed ID: 21047595
[TBL] [Abstract][Full Text] [Related]
7. Estimating lead time and overdiagnosis associated with PSA screening from prostate cancer incidence trends.
Telesca D; Etzioni R; Gulati R
Biometrics; 2008 Mar; 64(1):10-9. PubMed ID: 17501937
[TBL] [Abstract][Full Text] [Related]
8. Lead time of prostate cancer detected in population based screening for prostate cancer in Japan.
Ito K; Yamamoto T; Miyakubo M; Takechi H; Ohi M; Shibata Y; Suzuki K
J Urol; 2007 Oct; 178(4 Pt 1):1258-63; discussion 1263-4. PubMed ID: 17698107
[TBL] [Abstract][Full Text] [Related]
9. Summaries for patients. Screening smarter, not harder, for prostate cancer.
Ann Intern Med; 2013 Feb; 158(3):I-30. PubMed ID: 23381056
[No Abstract] [Full Text] [Related]
10. Interval cancers in prostate cancer screening: comparing 2- and 4-year screening intervals in the European Randomized Study of Screening for Prostate Cancer, Gothenburg and Rotterdam.
Roobol MJ; Grenabo A; Schröder FH; Hugosson J
J Natl Cancer Inst; 2007 Sep; 99(17):1296-303. PubMed ID: 17728218
[TBL] [Abstract][Full Text] [Related]
11. Prostate-specific antigen testing and prostate cancer screening.
Djavan B; Eckersberger E; Finkelstein J; Sadri H; Taneja SS; Lepor H
Prim Care; 2010 Sep; 37(3):441-59, vii. PubMed ID: 20705192
[TBL] [Abstract][Full Text] [Related]
12. Incidence of insignificant prostate cancer using free/total PSA: results of a case-finding protocol on 14,453 patients.
Pepe P; Aragona F
Prostate Cancer Prostatic Dis; 2010 Dec; 13(4):316-9. PubMed ID: 20714341
[TBL] [Abstract][Full Text] [Related]
13. Effects of prostate-specific antigen testing on familial prostate cancer risk estimates.
Bratt O; Garmo H; Adolfsson J; Bill-Axelson A; Holmberg L; Lambe M; Stattin P
J Natl Cancer Inst; 2010 Sep; 102(17):1336-43. PubMed ID: 20724726
[TBL] [Abstract][Full Text] [Related]
14. Prostate-specific antigen tests and prostate cancer screening: an update for primary care physicians.
Kell JS
Can J Urol; 2010 Feb; 17 Suppl 1():18-25. PubMed ID: 20170597
[TBL] [Abstract][Full Text] [Related]
15. Should prostate-specific antigen screening be offered to asymptomatic men?
van Vugt HA; Bangma CH; Roobol MJ
Expert Rev Anticancer Ther; 2010 Jul; 10(7):1043-53. PubMed ID: 20645694
[TBL] [Abstract][Full Text] [Related]
16. [Clinical value of prostate specific antigen screening in early detection of prostate cancer].
Hua LX; Qiao D; Song NH; Feng NH; Yang J; Zhang JX; Chen JG; Zhang W; Sui YG; Wu HF
Zhonghua Zhong Liu Za Zhi; 2009 Sep; 31(9):705-9. PubMed ID: 20021870
[TBL] [Abstract][Full Text] [Related]
17. Updated Japanese Urological Association Guidelines on prostate-specific antigen-based screening for prostate cancer in 2010.
;
Int J Urol; 2010 Oct; 17(10):830-8. PubMed ID: 20825509
[TBL] [Abstract][Full Text] [Related]
18. Critical appraisal of prostate-specific antigen in prostate cancer screening: 20 years later.
Pienta KJ
Urology; 2009 May; 73(5 Suppl):S11-20. PubMed ID: 19375622
[TBL] [Abstract][Full Text] [Related]
19. [Results and participation factors to the European Randomized study of Screening for Prostate Cancer (ERSPC) with Prostate Specific Antigen: French departments of Tarn and Hérault].
Jegu J; Tretarre B; Grosclaude P; Rebillard X; Bataille V; Malavaud B; Iborra F; Salama G; Rischmann P; Villers A
Prog Urol; 2009 Jul; 19(7):487-98. PubMed ID: 19559380
[TBL] [Abstract][Full Text] [Related]
20. Screening for prostate cancer: current recommendations.
Wilson SS; Crawford ED
Urol Clin North Am; 2004 May; 31(2):219-26. PubMed ID: 15123402
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
